Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Bactodac 2.5** is a Suncure Lifescience branded fixed-dose antibacterial injection containing ceftazidime 2 g and avibactam 0.5 g. Ceftazidime is a third-generation cephalosporin that inhibits bacterial cell-wall synthesis through penicillin-binding proteins, while avibactam inhibits bacterial beta-lactamases that would otherwise degrade ceftazidime. The combination is used for severe Gram-negative bacterial infections, including infections of the lungs, urinary tract, and abdomen. ([suncurelife.com](https://suncurelife.com/Key-Product-Detail/Bactodac%202_5.html))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ceftazidime + avibactam (Suncure Lifescience).